This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 'Listing regulation' ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pentokey Organy (India) Ltd's Board approved its unaudited financial results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations surged to Rs 506.20 lakhs, compared to nil in Q1 FY25 and Rs 60.62 lakhs in Q4 FY25 (full-year FY25 revenue was Rs 82.62 lakhs). Total income for the quarter stood at Rs 510.20 lakhs. Profit after tax came in at Rs 48.47 lakhs (vs Rs 4.60 lakhs in Q1 FY25 and Rs 24.55 lakhs for full-year FY25), translating to EPS of Rs 0.99. The company operates in the pharma/pesticides trading segment. Statutory auditor Verma Mehta & Associates issued an unmodified review report with no qualifications.
Sharp quarter-on-quarter jump in both revenue and profit signals a major scale-up in trading activity, which is positive for shareholders. However, the unusually low base in prior periods and dependence on stock-in-trade purchases warrant a closer look at sustainability of these earnings going forward.